218 related articles for article (PubMed ID: 24333120)
1. Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients.
Dhédin N; Krivine A; Le Corre N; Mallet A; Lioure B; Bay JO; Rubio MT; Agape P; Thiébaut A; Le Goff J; Autran B; Ribaud P
Vaccine; 2014 Jan; 32(5):585-91. PubMed ID: 24333120
[TBL] [Abstract][Full Text] [Related]
2. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
Le Corre N; Thibault F; Pouteil Noble C; Meiffrédy V; Daoud S; Cahen R; Charreau I; Bottigioli D; Dollinger C; Aboulker JP; Autran B; Morelon E; Barrou B
Vaccine; 2012 Dec; 30(52):7522-8. PubMed ID: 23103195
[TBL] [Abstract][Full Text] [Related]
3. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.
Engelhard D; Zakay-Rones Z; Shapira MY; Resnick I; Averbuch D; Grisariu S; Dray L; Djian E; Strauss-Liviatan N; Grotto I; Wolf DG; Or R
Vaccine; 2011 Feb; 29(9):1777-82. PubMed ID: 21216315
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients.
Mohty B; Bel M; Vukicevic M; Nagy M; Levrat E; Meier S; Grillet S; Combescure C; Kaiser L; Chalandon Y; Passweg J; Siegrist CA; Roosnek E; ;
Haematologica; 2011 Jun; 96(6):896-904. PubMed ID: 21422117
[TBL] [Abstract][Full Text] [Related]
5. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
[TBL] [Abstract][Full Text] [Related]
6. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients.
Ambati A; Einarsdottir S; Magalhaes I; Poiret T; Bodenstein R; LeBlanc K; Brune M; Maeurer M; Ljungman P
Transpl Infect Dis; 2015 Jun; 17(3):371-9. PubMed ID: 25817044
[TBL] [Abstract][Full Text] [Related]
8. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients.
Fairhead T; Hendren E; Tinckam K; Rose C; Sherlock CH; Shi L; Crowcroft NS; Gubbay JB; Landsberg D; Knoll G; Gill J; Kumar D
Transpl Infect Dis; 2012 Dec; 14(6):575-83. PubMed ID: 22999005
[TBL] [Abstract][Full Text] [Related]
9. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients.
Issa NC; Marty FM; Gagne LS; Koo S; Verrill KA; Alyea EP; Cutler CS; Koreth J; Armand P; Ho VT; Antin JH; Soiffer RJ; Baden LR
Biol Blood Marrow Transplant; 2011 Mar; 17(3):434-8. PubMed ID: 20950701
[TBL] [Abstract][Full Text] [Related]
10. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients.
Manuel O; Pascual M; Hoschler K; Giulieri S; Alves D; Ellefsen K; Bart PA; Venetz JP; Calandra T; Cavassini M
Clin Infect Dis; 2011 Jan; 52(2):248-56. PubMed ID: 21288852
[TBL] [Abstract][Full Text] [Related]
11. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation.
Gueller S; Allwinn R; Mousset S; Martin H; Wieters I; Herrmann E; Serve H; Bickel M; Bug G
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1546-50. PubMed ID: 21324375
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults.
Song JY; Cheong HJ; Seo YB; Kim IS; Noh JY; Heo JY; Choi WS; Lee J; Kim WJ
Clin Vaccine Immunol; 2012 May; 19(5):638-41. PubMed ID: 22379067
[TBL] [Abstract][Full Text] [Related]
13. Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.
Duval X; Caplanusi A; Laurichesse H; Deplanque D; Loulergue P; Vaman T; Launay O; Gillard P
BMC Infect Dis; 2012 Jul; 12():162. PubMed ID: 22824474
[TBL] [Abstract][Full Text] [Related]
14. Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Roll D; Ammer J; Holler B; Salzberger B; Schweiger B; Jilg W; Andreesen R; Edinger M; Wolff D; Holler E
Infection; 2012 Apr; 40(2):153-61. PubMed ID: 22038110
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with humoral immune response to pandemic A/H1N1(v) 2009 influenza vaccine in cystic fibrosis.
Launay O; Boelle PY; Krivine A; Grenet D; Boussaud V; Rémus N; Corvol H; Chedevergne F; Hubert D; Sermet-Gaudelus I;
Vaccine; 2014 Jul; 32(35):4515-4521. PubMed ID: 24950362
[TBL] [Abstract][Full Text] [Related]
16. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.
Ikematsu H; Nagai H; Kawashima M; Kawakami Y; Tenjinbaru K; Li P; Walravens K; Gillard P; Roman F
Hum Vaccin Immunother; 2012 Feb; 8(2):260-6. PubMed ID: 22426369
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina MJ; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
Lancet Infect Dis; 2011 Feb; 11(2):91-101. PubMed ID: 21168369
[TBL] [Abstract][Full Text] [Related]
18. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine.
Siegrist CA; Ambrosioni J; Bel M; Combescure C; Hadaya K; Martin PY; Soccal PM; Berney T; Noble S; Meier S; Posfay-Barbe K; Grillet S; Kaiser L; van Delden C;
Antivir Ther; 2012; 17(5):893-903. PubMed ID: 22544169
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
20. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
